by Richard Daverman, PhD
February 21, 2013 -- Beijing Double-Crane Pharmaceutical will invest 271 million RMB ($43 million) to build a fluid infusion manufacturing facility in Shanghai’s Jinshan Development Park. The plant will be operated by a subsidiary of Double-Crane, Shanghai Changzheng Fumin Jinshan Pharmaceutical Co. More details....
Stock Symbol: (SHE: 600062)
